GHRS vs GLSI

GH Research PLC vs Greenwich LifeSciences, Inc. — Valuation Comparison 2026

GHRS

Pharmaceutical Preparations
GH Research PLC
Quality
4.4
out of 10
Value Trap
12
SAFE
Price
$23.99
Last close
Models
7/13
Active
VS

GLSI

Pharmaceutical Preparations
Greenwich LifeSciences, Inc.
Quality
4.0
out of 10
Value Trap
Price
$26.18
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType GHRS Fair ValueGHRS Upside GLSI Fair ValueGLSI Upside
Bayesian DCF Intrinsic $3.64 -84.8% $7.40 -71.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.62 -89.1% $0.58 -97.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GHRS vs GLSI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GHRS vs GLSI — Which Stock Is More Undervalued?

GHRS scores higher with a 4.4/10 quality rating vs GLSI's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing GH Research PLC (GHRS) and Greenwich LifeSciences, Inc. (GLSI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GHRS currently trades at $23.99 with a QOC of 4.4/10, while GLSI trades at $26.18 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).